Abstract：Objective To investigate the incidence of adverse events following immunization (AEFI) with inactivated influenza vaccine among the elderly in Huzhou City, Zhejiang Province, so as to provide insights into safety monitoring and evaluation of inactivated influenza vaccines. Methods Data pertaining to surveillance on AEFI with inactivated influenza vaccines among the elderly at ages of 60 years and older in Huzhou City from 2020 to 2022 were collected from the AEFI Monitoring Information Management System of the Immunization Planning System of Chinese Disease Control and Prevention Information System, including demographics, time of AEFI occurrence, classification of AEFI and clinical syndromes, and the reported incidence and epidemiological features of AEFI with inactivated influenza vaccines were analyzed using a descriptive epidemiological method. Results Totally 84 elderly cases at ages of 60 years and older were reported with AEFI with inactivated influenza vaccines in Huzhou City from 2020 to 2022, with a reported incidence rate of 9.83/105 doses, and the reported incidence rates of AEFI with trivalent and quadrivalent inactivated influenza vaccines were 9.74/105 doses and 48.71/105 doses, respectively. The reported incidence rates of general, abnormal, coincidence and psychogenic reactions were 7.96/105 doses, 1.52/105 doses, 0.23/105 doses and 0.12/105 doses, respectively, and no vaccine quality accidents or wrong vaccine administered were reported. The cases with AEFI included 52 women and 32 men, and most cases were aged from 60 to 69 years (44 cases, 52.38%). The highest incidence of AEFI was reported in Nanxun District (17.94/105 doses), and there were 79 cases (94.05%) with AEFI within 24 hours following vaccination. The clinical symptoms mainly included fever, local redness and swelling, and local induration, with reported incidence rates of 2.22/105 doses, 3.74/105 doses, and 1.99/105 doses, respectively. Conclusions The reported incidence of AEFI with inactivated influenza vaccines is low among the elderly at ages of 60 years and older in Huzhou City, with general reactions as predominant AEFI, and most AEFI occurs within 24 hours following vaccination.
张超, 罗小福, 刘艳, 沈建勇, 徐秦儿, 韩利萍, 马力. 湖州市老年人接种流感灭活疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(8): 701-704.
ZHANG Chao, LUO Xiaofu, LIU Yan, SHEN Jianyong, XU Qin'er, HAN Liping, MA Li. Surveillance of adverse events following immunization with inactivated influenza vaccines among the elderly in Huzhou City. Preventive Medicine, 2023, 35(8): 701-704.
[1] 付小强,颜娜,徐小玲,等.鄂州市居民流感疫苗接种意愿及影响因素分析[J].预防医学,2022,34(12):1273-1278,1282. [2] 中华预防医学会流感疫苗保护效果真实世界研究共识专家组.流行性感冒疫苗保护效果真实世界研究专家共识[J].中国疫苗和免疫,2022,28(6):617-637. [3] 田诚,史鲁斌,杨凯朝,等.河南省2017—2020年不同流感疫苗预防接种不良反应发生率[J].中国疫苗和免疫,2021,27(4):420-423. [4] MONTOMOLI E,TORELLI A,MANINI I,et al.Immunogenicity and safety of the new inactivated quadrivalent influenza vaccine vaxigrip tetra:preliminary results in children≥6 months and older adults[J/OL].Vaccine,2018,6(1)[2023-06-27].https://doi.org/10.3390/vaccines6010014. [5] 国家免疫规划技术工作组流感疫苗工作组.中国流感疫苗预防接种技术指南(2022—2023)[J].中华流行病学杂志,2022,43(10):1515-1544. [6] STATLER V A,ALBANO F R,AIREY J,et al.Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age:a phase 3,randomized,noninferiority study[J].Vaccine,2019,37(2):343-351. [7] 胡昱,李倩,陈雅萍,等.18岁以上人群接种四价流感病毒灭活疫苗免疫原性和安全性的Meta分析[J].国际流行病学传染病学杂志,2017,44(1):47-52. [8] 中华人民共和国卫生部办公厅,国家食品药品监督管理局办公室.全国疑似预防接种异常反应监测方案[Z/OL].[2023-06-27].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/qita/20100603120001618_3.html. [9] 张婷,梁文佳,邱泉,等.2019—2021年广东省流感疫苗疑似预防接种异常反应监测分析[J].华南预防医学,2022,48(7):867-870. [10] 刘艳,杜渐,许玉洋,等.杭州市2019—2021年灭活流感疫苗疑似预防接种异常反应监测[J].中国公共卫生,2022,38(10):1322-1326. [11] 武文娣,李克莉,许涤沙,等.中国2015—2018年3个流感季节流感疫苗疑似预防接种异常反应监测数据分析[J].中华预防医学杂志,2019,53(10):987-992. [12] 刘书珍,孟丽,席佩佩,等.四价流感病毒裂解疫苗安全性和免疫原性评价[J].预防医学,2020,32(11):1091-1095. [13] VAN DE WITTE S,NAUTA J,MONTOMOLI E,et al.A phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects,assessing both antihaemagglutinin and virus neutralisation antibody responses[J].Vaccine,2018,36(40):6030-6038. [14] 丁林玲,何寒青,邱春华,等.2018—2019年台州市社区≥60岁老年人三价流感病毒裂解疫苗预防接种不良事件观察[J].中国疫苗和免疫,2020,26(4):383-386. [15] 何奔,向泽林,沈国初,等.老年人单独及联合接种流感疫苗、23价肺炎球菌多糖疫苗的安全性评价[J].中华微生物学和免疫学杂志,2018,38(4):293-299. [16] 夏娇慧,赵淑洁,王平,等.4个地区四价流感病毒裂解疫苗上市后的安全性评价[J].微生物学免疫学进展,2022,50(2):41-46. [17] 张丽娜,李克莉,李燕,等.2020年中国疑似预防接种异常反应监测[J].中国疫苗和免疫,2022,28(2):208-218.
